Amir Nashat
CEO
Soufflé Therapeutics
Cell-specific RNA therapies via receptor-mediated delivery
Community-submitted · content unverified. This organization has not verified ownership or the information in this profile.
About
Soufflé Therapeutics is a Boston biotechnology company building RNA therapies designed for cell-specific delivery outside the liver. Its REMEDY (Receptor Mediated Delivery) engine identifies internalizing receptors and generates proprietary binders to deliver oligonucleotide therapies to target cells and tissues. Programs include striated muscle for FSHD and cardiomyocytes for heart failure (HFrEF), among other muscle and metabolic disorders. On 13 October 2026 it raised $135 million in Series B financing led by Juvia Group, with participation from TCG Crossover, BB Biotech, Fidelity, Amgen Ventures, ARCH Venture Partners, Bessemer, Temasek, Leaps by Bayer, and others. CEO Amir Nashat leads the company.
- Website
- souffletx.com
- Stage
- series-b+
- Location
- Boston, MA, USA
- Added via
- web
- Ownership
- unclaimed